The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.
Thure Filskov OvervadFlemming SkjøthGregory PiazzaSimon NobleAnne Gulbech OrdingTorben Bjerregaard LarsenPeter Brønnum NielsenPublished in: Journal of thrombosis and haemostasis : JTH (2022)
The Khorana score was able to risk stratify patients with cancer treated with immune checkpoint inhibitors according to 6-month risk of thromboembolic events. Risks of venous thromboembolism were lower than in randomized thromboprophylaxis trials, thus questioning the absolute benefit of routine primary thromboprophylaxis in an unselected population of patients treated with immune checkpoint inhibitors.